Table 1.
Characteristics of the included studies.
| Author, year | Panel | Participants no. | Female (%) | Mean age | Nodule size (cm) | Bethesda category | NIFTP no. (result) | Conflicts of interest |
|---|---|---|---|---|---|---|---|---|
| Alexander, 2012 (8) | AGEC | 379 | 81.7 | 53,2 | 2,2 | III, IV, V | N/A | Yes |
| Alexander, 2014 (47) | AGEC | 339 | 79 | 55 | 2,2 | III, IV, V | N/A | Yes |
| Al-qurayshi, 2016 (48) | AGEC | 145 | 73 | 56,0 | 2,4 | III, IV | N/A | Yes |
| Arosemena, 2019 (49) | AGEC | 117 | 80 | 58,0 | 2,03 | III | 0 | No |
| Azizi, 2018 (50) | AGEC | 151 | 89 | 51,4 | 1,65 | III, IV | N/A | No |
| Baca, 2017 (51) | AGEC | 229 | 78 | 56,3 | 1,8 | III | 15 (+) | Yes |
| Brauner, 2015 (52) | AGEC | 72 | 81 | 59,2 | 2,2 | III, V (HC) | N/A | Yes |
| Celik, 2015 (53) | AGEC | 46 | 71.2 | 59,4 | ? | III, IV, V | N/A | No |
| Chaudhary, 2016 (54) | AGEC | 158 | ? | ? | ? | III, IV | N/A | No |
| Chen, 2019 (55) | TQ3 | 51 | 74 | 54 | 2,5 | III, IV | N/A | No |
| Deaver, 2018 (56) | AGEC | 167 | ? | ? | ? | III, IV | 2 (+) | Yes |
| Endo, 2019 (17) | AGEC | 317 | 77.5 | 52,1 | 2,23 | III, IV | 6 (+) | No |
| AGSC | 153 | 75 | 54,9 | 2,3 | III, IV | 1 (+) | No | |
| Harrell, 2018 (57) | AGEC | 481 | ? | ? | ? | III, IV | 0 | Yes |
| AGSC | 139 | ? | ? | ? | III, IV | 1 (−) | Yes | |
| Jug, 2018 (58) | AGEC | 207 | 78 | 57 | 1.1-5.3 | III, IV, V | 4 (+) | No |
| TQ2 | 97 | 80 | 59, | 1.1-5.3 | III, IV, V | 4 (+) | No | |
| Jug, 2020 (59) | TQ3 | 91 | 81 | 58,9 | ? | III, IV | 2 (+) | No |
| TQ2 | 94 | 80 | 58,1 | ? | III, IV | 2 (+) | No | |
| Labourier, 2015 (21) | MPT | 109 | 74 | 56 | – | III, IV | N/A | Yes |
| Lithwick, 2016 (60) | Rosetta | 201 | 80 | 53 | > 0,5 | III, IV, V | N/A | Yes |
| Livhits, 2018 (61) | AGEC | 70 | 81.4 | 61 | 2,0 | III, IV (HC) | 6 (+) | No |
| TQ2 | 79 | 83 | 57 | 2,1 | III, IV | 2 (+) | No | |
| Lupo, 2020 (23) | MPTX | 197 | 73 | 55 | 2,3 | III, IV, V | 5 (+) | Yes |
| Marcadis, 2018 (62) | TQ2 | 266 | 75 | 53 | 2,7 | III, IV | 38 (+), 8 (−) | No |
| Marti, 2015 (63) | AGEC | 156 | 88.4 | 51.7 | 2.17 | III, IV | N/A | No |
| Mciver, 2014 (64) | AGEC | 72 | ? | ? | ? | III, IV (HC) | N/A | No |
| Nikiforov, 2014 (11) | TQ2 | 143 | ? | ? | ? | IV | N/A | Yes |
| Nikiforov, 2015 (15) | TQ2 | 441 | ? | ? | ? | III | N/A | Yes |
| Nikiforova, 2018 (65) | TQ3 | 175 | ? | ? | ? | III, IV, V | 6 ()? | Yes |
| Papoian, 2020 (66) | AGEC | 69 | 87 | 50 | 1,9 | III | N/A | No |
| Partyka, 2019 (68) | AGEC | 68 | 75 | 12-81 | ? | III, IV | 4 (+) | No |
| MPT | 22 | 63 | 18-77 | ? | III, IV, V | 1 (+) | No | |
| Rosetta | 23 | 78 | 19-68 | ? | III, IV, V | 1 (+) | No | |
| Partyka, 2018 (67) | AGEC, MPT, Rosetta | 10 | 70 | 25-65 | ? | III, IV, V | N/A | No |
| Patel, 2018 (16) | AGSC | 183 | 77.6 | 51,7 | 2,6 | III, IV | N/A | Yes |
| Sacks, 2016 (69) | AGEC | 140 | 73,5 | 58, | 2 | III, IV | N/A | Yes |
| Samulski, 2016 (40) | AGEC | 294 | ? | ? | ? | III, IV, HC | 10 (+) | Yes |
| San Martin, 2019 (70) | AGEC | 178 | 63 | 59 | 2,0 | III, IV | N/A | No |
| AGSC | 121 | 75 | 56,1 | 2,0 | III, IV | N/A | No | |
| Shrestha, 2016 (71) | TQ2 | 45 | 77,2 | 48 | ? | III, IV, V | N/A | Yes |
| Steward, 2018 (14) | TQ3 | 232 | 79 | 53,0 | 2,4 | III, IV, V | 11 (+) | Yes |
| Sultan, 2016 (72) | AGEC | 48 | 80 | 54,3 | 2,49 | III, IV | 4 (+) | No |
| Taye, 2018 (73) | TQ2 | 151 | 79 | 52 | 2,6 | III, IV | 2 (+), 1(−) | No |
| Valderrabano, 2016 (74) | miRInform | 105 | 82 | 56 | 2,6 | III, IV, V | N/A | Yes |
| Valderrabano, 2017 (75) | TQ2 | 182 | 76 | 56,2 | ? | III, IV | 6 (+), 2(−) | Yes |
| Wang, 2020 (76) | AGEC | 281 | 81 | 51 | 2,4 | III, IV | N/A | No |
| Wu, 2016 (77) | AGEC | 230 | 80 | 51,9 | ? | III, IV | N/A | Yes |
AGEC, Afirma Gene Expression Classifier; AGSC, Afirma Gene Sequencing Classifier; cPTC, classic papillary thyroid cancer; E-FVPTC, Encapsulated FVPTC; FVPTC, follicular variant of papillary thyroid cancer; FTC, follicular thyroid cancer; HC, Hurthle cell predominant; HCC, Hurthle cell carcinoma; I-FVPTC, Infiltrative FVPTC; MI, minim invasive; OVPTC, Oncocytic variant papillary thyroid cancer; MPT, Multiplatform Test (ThyraMIR/ThyGenX); MPTX, ThyraMIR/ThyGeNEXT; MTC, medullary thyroid cancer; N/A, Not available; NIFTP, Noninvasive follicular thyroid neoplasm with papillary like nuclear features; no., number; PDTC, poorly differentiated thyroid cancer; Pro, Prospective, PTC, Papillary thyroid cancer; Retro, Retrospective; TC, thyroid cancer; TQ2, ThyroseQ version 2; TQ3, ThyroseQ version 3.